Q&A with Alondra Nelson
By Misha Angrist,
Genome Magazine
| 03. 30. 2017
Why did you choose to examine African-Americans’ approach to genetic ancestry in The Social Life of DNA?
Given the Tuskegee syphilis experiment, given the history of eugenics, one of the curiosities for me was why in the world would African-Americans put their saliva in an envelope and expect that they’re going to get anything meaningful for their lives or their history [from a genetic ancestry] test? That became the puzzle of the book.
What did you learn?
That there were all sorts of complicated answers. The African-American genealogists I spoke with were not only suspicious, they were also curious — they were science geeks. I thought if they knew better, then they would do better. But what they said was, “Look, we know this history [of Tuskegee and eugenics] and we’re going into this with that history in mind, and we’ll take that into account as we negotiate and think about the results we get back.”
What does it mean for DNA to have a “social life?”
Initially, I thought I was talking about racial identity and ethnic identity. And...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 06.11.2026
When scientists at Columbia University announced they had used a newer technology to precisely edit the genes of human embryos last week, they set the academic community ablaze with debate. Is this good news or bad? How fast will...
By Gina Kolata, The New York Times | 06.11.2026
On my second visit with Nancy Wexler at her Manhattan apartment, she had a gift for me. It was a copy of her newly published memoir, “My Life, My Science: Pursuing a Cure for Huntington’s Disease.”
It had been signed...
By Samuelle Fajutrao Falk , The Conversation | 06.26.2026
When my colleagues and I asked autistic people and parents of autistic children in Sweden how they feel about genetic research in autism, one response stood out: “I hope genetic research finds new ways to help us, not erase us.”...
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...